Question 1

Clinical Significance

Accepted Answer

Determining eligibility for targeted therapies like Trastuzumab. Assessing tumor aggressiveness and growth rate. Developing a personalized treatment plan based on molecular characteristics.

Question 2

Target Groups

Accepted Answer

Patients newly diagnosed with breast cancer. Patients with gastric or gastroesophageal junction cancer. Recurrent cancer cases to re-evaluate protein status.

Question 3

Understanding Your Results

Accepted Answer

Score 0 or 1+: Considered HER2-negative. Score 2+: Considered equivocal (requires further FISH testing). Score 3+: Considered HER2-positive (eligible for targeted therapy).

Your Guide to Targeted Therapy - HER2/neu Protein Overexpression (IHC) Test